Skip to content
Open in App
Novo Nordisk AS DRC logo

Novo Nordisk AS DRC

web2

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manu...

Symbol · NVON
Company profile

About

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Explore by sector

Explore this sector

Presentation

Watch Novo Nordisk AS DRC

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Wegovy pill surpasses three million US prescriptions

KEY STEP

Novo Nordisk announced that Wegovy tablets had surpassed three million prescriptions in the United States in just over five months since launch. The company also stated that the majority of new prescriptions were for people previously new to GLP 1 therapy.

Roadmap reference

European committee recommends oral Wegovy for weight management

KEY STEP

The European Medicines Agency committee adopted a positive opinion recommending Wegovy tablets as an oral formulation for weight management, creating a regulatory path toward broader European availability.

Roadmap reference

European Commission approves Wegovy pill and Wegovy 7.2 mg

KEY STEP

Novo Nordisk announced European Commission marketing authorisation for once daily Wegovy pill for weight management and for the higher dose Wegovy 7.2 mg injection in a single dose pen. The approvals expand the Wegovy franchise across oral and higher dose injectable formulations in the European Union.

Roadmap reference
People

Company team

LR

Lars Rebien Sorensen

Chair of Board

Company leadership profile.

Cd

Cornelis de Jong

Independent Vice Chair of the Board

Company leadership profile.

SE

Stephan Engels

Independent Director

Company leadership profile.

DJ

Desirée Jantzen Asgreen

Employee Representative Director

Company leadership profile.

MB

Mette Bojer Jensen

Employee Non-Independent Representative Director

Company leadership profile.

KK

Kasim Kutay

Non-Independent Director

Company leadership profile.

ED

Elisabeth Dahl Christensen

Employee Representative Director

Company leadership profile.

BM

Britt Meelby Jensen

Director

Company leadership profile.

RS

Ramona Sequeira

Director

Company leadership profile.

SK

Semsi Kilic Madsen

Employee Representative Director

Company leadership profile.

HI

Helena IIdiko Saxon

Independent Director

Company leadership profile.

PW

Poul Weihrauch

Board Observer

Company leadership profile.

JG

Jan G.J. van de Winkel

Director

Company leadership profile.

AK

Anders Kaae

Substitute Director

Company leadership profile.

KB

Karina Bonde Lenau

Substitute Director

Company leadership profile.

JT

Jesper Thorning

Substitute Director

Company leadership profile.

TV

Tanja Villumsen

Substitute Director

Company leadership profile.

HK

Hassan Kassem

Substitute Director

Company leadership profile.

TH

Trine Hartvig Kristiansen

Substitute Director

Company leadership profile.

TS

Tamara Schmidt

Substitute Director

Company leadership profile.

Expert coverage

2 experts evaluated Novo Nordisk AS DRC.

Orbitrum research

Experts evaluating Novo Nordisk AS DRC

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment